Chemical Engineering Department, Northeastern University, Boston, MA 02115, USA.
Nanoscale. 2019 Aug 15;11(32):15057-15071. doi: 10.1039/c9nr03931g.
To date, the delivery of therapeutic agents for malignant brain tumors (such as glioblastoma multiforme (GBM)) remains a significant obstacle due to the existence of the blood-brain barrier (BBB). A multitude of delivery systems (hydrogels, micelles, polymeric nanoparticles, etc.) have been proposed, yet many of them exhibit limited tumor-specific inhibition effects. Herein, a drug-encapsulated dual-functionalized thermosensitive liposomal system (DOX@P1NS/TNC-FeLP) was developed for targeted delivery across the BBB. Specifically, a GBM-specific cell-penetrating peptide (P1NS) and an anti-GBM antibody (TN-C) were conjugated onto the liposome surface for targeted delivery. In addition, superparamagnetic iron oxide nanoparticles (SPIONs) and doxorubicin (DOX) were co-loaded inside the liposomes to achieve thermo-triggered drug release when applying an alternating magnetic field (AMF). Results demonstrated that P1NS/TNC-FeLPs readily transported across an in vitro BBB model and displayed a thermo-responsive and GBM-specific cellular uptake as well as drug release profile. Additionally, results from immunofluorescent (IF) staining and RT-qPCR further demonstrated that DOX@P1NS/TNC-FeLPs specifically entered U-87 human GBM cells and suppressed tumor cell proliferation without causing any significant impact on healthy brain cell function. As such, the novel DOX@P1NS/TNC-FeLPs presented potent and precise anti-GBM capability and, therefore, are suggested here for the first time as a promising DDS to deliver therapeutic agents across the BBB for GBM treatment.
迄今为止,由于血脑屏障(BBB)的存在,恶性脑肿瘤(如多形性胶质母细胞瘤(GBM))的治疗药物传递仍然是一个重大障碍。已经提出了多种传递系统(水凝胶、胶束、聚合物纳米颗粒等),但其中许多系统表现出有限的肿瘤特异性抑制作用。在此,开发了一种载药双重功能热敏脂质体系统(DOX@P1NS/TNC-FeLP)用于靶向穿过 BBB 的递药。具体来说,将一种 GBM 特异性细胞穿透肽(P1NS)和抗 GBM 抗体(TN-C)接枝到脂质体表面以进行靶向递药。此外,超顺磁氧化铁纳米颗粒(SPIONs)和阿霉素(DOX)被共载于脂质体内,以在施加交变磁场(AMF)时实现热触发药物释放。结果表明,P1NS/TNC-FeLPs 易于穿过体外 BBB 模型,并表现出热响应和 GBM 特异性细胞摄取以及药物释放特性。此外,免疫荧光(IF)染色和 RT-qPCR 的结果进一步表明,DOX@P1NS/TNC-FeLPs 特异性进入 U-87 人 GBM 细胞,并抑制肿瘤细胞增殖,而对健康脑细胞功能没有任何显著影响。因此,新型 DOX@P1NS/TNC-FeLPs 表现出强大而精确的抗 GBM 能力,因此,本文首次提出将其作为一种有前途的 DDS,用于通过 BBB 递药治疗 GBM。